Emerging Credit Rating Limited (ECRL) has affirmed AA+ (Pronounced as Double A Plus) long term credit rating and ST-1 short term credit rating to Eskayef Pharmaceuticals Limited. The outlook of the rating is Stable. The ratings are consistent with ECRL’s methodology for this type of company. The rating is based on the audited financial statements for FY2022-2025 and other relevant qualitative and quantitative information up to the date of rating. The rating is valid from March 17, 2026 to March 16, 2027. The ratings may be changed or revised prior to expiry, if warranted by extraordinary circumstances in the management, operations and/or performance of the entity rated.